HUTCHMED has announced positive results from the FRUSICA-2 Phase II/III trial evaluating fruquintinib in combination with sintilimab as a second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC). The study met its primary endpoint, showing a significant improvement in progression-free survival (PFS) versus standard therapies, and will be presented at the upcoming ESMO 2025 Congress in Berlin. The combination achieved a median PFS of 22.2 months versus 6.9 months with s ....
